The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer

by Dingzhi Huang, Caicun Zhou, Gisoo Barnes, Yiyuan Ma, Songzi Li, Lin Zhan, Boxiong Tang
Published 2023-08-01

Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.

by Morgan Kruse, Rebecca Wildner, Gisoo Barnes, Monique Martin, Udo Mueller, Francesco Lo-Coco, Ashutosh Pathak
Published 2015-01-01

Real‐World longitudinal practice patterns in the use of PD‐1 and PD‐L1 inhibitors as First‐Line therapy in patients with Non‐Small cell lung cancer in the United States

by Rajwanth Veluswamy, Fred R. Hirsch, Emanuela Taioli, Juan Wisnivesky, Ross Strauss, Douglas Harrough, Boxiong Tang, Gisoo Barnes
Published 2022-11-01

P640: ZANUBRUTINIB VS IBRUTINIB IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND SMALL LYMPHOCYTIC LYMPHOMA (R/R CLL/SLL): IMPACT ON HEALTH-RELATED QUALITY OF LIFE (HRQOL)

by Barbara Eichhorst, Nicole Lamanna, Susan O’brien, Constantine Tam, Lugui Qiu, Keri Yang, Ken Wu, Tommi Salmi, Gisoo Barnes, Jennifer R. Brown
Published 2023-08-01

Tislelizumab vs sorafenib in first-line treatment of unresectable hepatocellular carcinoma: impact on health-related quality of life in RATIONALE-301 study

by Richard S. Finn, Masatoshi Kudo, Gisoo Barnes, Tim Meyer, Frederic Boisserie, Ramil Abdrashitov, Yaxi Chen, Songzi Li, Andrew X. Zhu, Shukui Qin, Arndt Vogel
Published 2024-02-01

P1679: HEALTH-RELATED QUALITY OF LIFE IN PATIENTS (PTS) WITH WALDENSTRÖM MACROGLOBULINEMIA (WM) TREATED WITH ZANUBRUTINIB (ZANU) VS IBRUTINIB (IBR): RESULTS FROM THE PHASE 3 ASPEN...

by Alessandra Tedeschi, Constantine Tam, Roger Owen, Christian Buske, Véronique Leblond, Meletios A. Dimopoulos, Ramón García-Sanz, Jorge Castillo, Judith Trotman, Steven Treon, Keri Yang, Boxiong Tang, Heather Allewelt, Sheel Patel, Wai Chan, Aileen Cohen, Jingjing Yan Schneider, Gisoo Barnes
Published 2023-08-01